Earnings Review - Arrowhead Research

LONDON, December 17, 2014 /PRNewswire/ --

Investor-Edge.com has issued free earnings review on Arrowhead Research Corp. (NASDAQ: ARWR). On November 25, 2014, the company reported its Q4 FY14 and full-year FY14 financial results (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on Arrowhead Research Corp. (Arrowhead). During FY14, Arrowhead's revenue fell by $115,266 from the preceding year. Our free coverage report can be accessed at:

www.investor-edge.com/register

Earnings Overview 

During FY14, Arrowhead's revenue declined to $175,000 from $290,266 in the previous year. The company's FY14 revenue fell short of Bloomberg analysts' forecasts of $182,250. The free research on ARWR can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Arrowhead%20Research&d=17-Dec-2014&s=ARWR

The company's total operating expenses for FY14 increased to $53.45 million from $24.88 million in FY13, primarily due to a rise in research and development expenses which grew to $23.14 million in FY14 from $8.71 million in the preceding year. During FY14, Arrowhead reported an operating loss of $53.28 million compared to an operating loss of $24.59 million reported in FY13. Further, the company's FY14 net loss increased to $58.73 million from a net loss of $31.70 million in the previous year. On a per share basis, Arrowhead reported a net loss of $1.25 per basic and diluted share, compared to a net loss of $1.30 per basic and diluted share reported in FY13. Analysts from Bloomberg had expected the company to report net loss of $43.35 million, or $1.05 per basic and diluted share, in FY14.

During the reported quarter, Arrowhead signed an agreement with The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation. Under the terms of the agreement, TAP will partially fund the development of the Company's therapeutic candidate ARC-AAT. In addition, TAP will make its scientific advisors available to Arrowhead, assist the company with patient recruitment for clinical trials through the Alpha-1 Foundation Patient Research Registry, and engage in other collaborative efforts that support the development of ARC-AAT. Sign up and read the free analyst's notes on ARWR at:

http://get.Investor-Edge.com/pdf/?c=Arrowhead%20Research&d=17-Dec-2014&s=ARWR

As of September 30, 2014, the company had total cash resources (cash, cash equivalent and investments) of $177.25 million, compared to $29.85 million as of September 30, 2013.

Stock Performance  

On the day following the earnings release, November 26, 2014, Arrowhead's stock ended the session at $5.78, down 1.03%. Since then, shares of the company have witnessed a mixed momentum. On the last close, Tuesday, December 16, 2014, Arrowhead's shares finished 7.52% higher at $5.86. The company's shares vacillated between $5.42 and $6.19 during the session. A total of 2.80 million shares were traded, which was below its three months average volume of 3.90 million shares. The company's shares have lost 1.18% in the previous three trading sessions and 2.98% in the last one month. Further, the stock has declined 45.99% since the start of this year. Shares in Arrowhead closed below their 50-day and 200-day moving averages of $6.44 and $12.49, respectively. Furthermore, the stock has a Relative Strength Index (RSI) of 42.93. Visit Investor-Edge and access the latest research on ARWR at:

http://get.Investor-Edge.com/pdf/?c=Arrowhead%20Research&d=17-Dec-2014&s=ARWR

Sneak Peek to Corporate Insider Trading 

In the last one month Arrowhead has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on ARWR is available at:

http://get.Investor-Edge.com/pdf/?c=Arrowhead%20Research&d=17-Dec-2014&s=ARWR

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED